ANI Pharmaceuticals Inc. (ANIP) Decreased by the The Zacks Investment Research to Sell

ANI Pharmaceuticals Inc. (ANIP) Decreased by the The Zacks Investment Research to Sell

Zacks Investment Research lowered shares of ANI Pharmaceuticals Inc. (NASDAQ:ANIP) from a hold rating to a sell rating in a research report released on Tuesday morning.

According to Zacks, “ANI Pharmaceuticals, Inc. is a specialty pharmaceutical company. It engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The company offers liquid, powder, oral solid dose, cough/cold products, antacids, laxatives, stomach remedies as well as hydrocortisone retention enema, esterified estrogen and methyltestosterone, fluvoxamine maleate tablets, hydrocortisone rectal suspension, metoclopramide oral solution, opium tincture and metoclopramide tablets. In addition, it offers contract manufacturing services for other pharmaceutical companies. The company serves through wholesalers, smaller regional distributors and chains and pharmacy and retail outlets primarily in the United States. ANI Pharmaceuticals, Inc., formerly known as BioSante Pharmaceuticals, Inc., is headquartered in Baudette, MN. “

Several other equities analysts also recently weighed in on the company. TheStreet upgraded ANI Pharmaceuticals from a hold rating to a buy rating in a research report on Friday, August 26th. Guggenheim reiterated a buy rating and set a $80.00 target price (up from $65.00) on shares of ANI Pharmaceuticals in a research report on Friday, August 5th. Oppenheimer Holdings Inc. increased their target price on ANI Pharmaceuticals from $65.00 to $71.00 and gave the stock an outperform rating in a research report on Friday, August 5th. Finally, Citigroup Inc. upgraded ANI Pharmaceuticals to an outperform rating and set a $65.00 target price on the stock in a research report on Tuesday, July 19th. One analyst has rated the stock with a sell rating, one has given a hold rating, four have issued a buy rating and two have issued a strong buy rating to the company. ANI Pharmaceuticals currently has a consensus rating of Buy and an average target price of $67.00.

ANI Pharmaceuticals (NASDAQ:ANIP) opened at 57.57 on Tuesday. The firm has a market capitalization of $666.66 million, a P/E ratio of 84.29 and a beta of 3.22. ANI Pharmaceuticals has a 12 month low of $26.80 and a 12 month high of $70.92. The stock’s 50 day moving average price is $63.46 and its 200-day moving average price is $58.70.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings data on Thursday, November 3rd. The specialty pharmaceutical company reported $1.09 EPS for the quarter, beating analysts’ consensus estimates of $1.08 by $0.01. The business had revenue of $38.53 million for the quarter, compared to analyst estimates of $34.34 million. ANI Pharmaceuticals had a return on equity of 21.84% and a net margin of 7.28%. The business’s revenue for the quarter was up 92.9% compared to the same quarter last year. During the same quarter last year, the company earned $0.80 earnings per share. On average, analysts forecast that ANI Pharmaceuticals will post $4.06 earnings per share for the current year.

In other news, insider Arthur Przybyl sold 37,455 shares of the firm’s stock in a transaction dated Monday, August 22nd. The stock was sold at an average price of $66.97, for a total value of $2,508,361.35. Following the transaction, the insider now directly owns 200,788 shares in the company, valued at approximately $13,446,772.36. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 31.60% of the stock is owned by insiders.

Institutional investors have recently added to or reduced their stakes in the company. Municipal Employees Retirement System of Michigan increased its position in ANI Pharmaceuticals by 0.8% in the third quarter. Municipal Employees Retirement System of Michigan now owns 3,560 shares of the specialty pharmaceutical company’s stock worth $236,000 after buying an additional 30 shares during the period. American International Group Inc. increased its stake in shares of ANI Pharmaceuticals by 1.0% in the third quarter. American International Group Inc. now owns 5,895 shares of the specialty pharmaceutical company’s stock valued at $391,000 after buying an additional 56 shares during the last quarter. ProShare Advisors LLC increased its stake in shares of ANI Pharmaceuticals by 0.8% in the second quarter. ProShare Advisors LLC now owns 9,692 shares of the specialty pharmaceutical company’s stock valued at $541,000 after buying an additional 81 shares during the last quarter. Rhumbline Advisers increased its stake in shares of ANI Pharmaceuticals by 2.0% in the second quarter. Rhumbline Advisers now owns 10,080 shares of the specialty pharmaceutical company’s stock valued at $563,000 after buying an additional 194 shares during the last quarter. Finally, Arizona State Retirement System increased its stake in shares of ANI Pharmaceuticals by 5.1% in the third quarter. Arizona State Retirement System now owns 4,115 shares of the specialty pharmaceutical company’s stock valued at $273,000 after buying an additional 200 shares during the last quarter. Institutional investors own 50.49% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company’s focused areas of product development include anti-cancer (oncolytics), hormones and steroids, and complex formulations.

Related posts

Leave a Comment